Evidence map›Paper›PMID 39330662›Full record

ArticleNanomaterials (Basel, Switzerland)2024

The Remarkable and Selective In Vitro Cytotoxicity of Synthesized Bola-Amphiphilic Nanovesicles on Etoposide-Sensitive and -Resistant Neuroblastoma Cells.

Silvana Alfei, Paolo Giannoni, Maria Grazia Signorello, Carola Torazza, Guendalina Zuccari, Constantinos M Athanassopoulos, Cinzia Domenicotti, Barbara Marengo

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvana AlfeiDepartment of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.ORCID 0000-0002-4630-4371
Paolo GiannoniDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0000-0002-7206-376X
Maria Grazia SignorelloBiochemistry Laboratory, Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy.
Carola TorazzaDepartment of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.
Guendalina ZuccariDepartment of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.ORCID 0000-0002-9868-6199
Constantinos M AthanassopoulosDepartment of Chemistry, Campus Rio Achaias, University of Patras, 26504 Rio, Greece.ORCID 0000-0002-7549-1911
Cinzia DomenicottiDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0000-0002-5003-7333
Barbara MarengoDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0000-0003-3056-6569

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma (NB) is a solid tumor occurring in infancy and childhood. Its high-risk form has currently a survival rate <50%, despite aggressive treatments. This worrying scenario is worsened by drug-induced secondary tumorigenesis and the emergency of drug resistance, calling for the urgent development of new extra-genomic treatments. Triphenyl phosphonium salts (TPPs) are mitochondria-targeting compounds that exert anticancer effects, impair mitochondria functions, and damage DNA at the same time. Despite several biochemical applications, TPP-based bola-amphiphiles self-assembling nanoparticles (NPs) in water have never been tested as antitumor agents. Here, with the aim of developing new antitumor devices to also counteract resistant forms of HR-NB, the anticancer effects of a TPP-based bola-amphiphile molecule have been investigated in vitro for the first time. To this end, we considered the previously synthesized and characterized sterically hindered quaternary phosphonium salt (BPPB). It embodies both the characteristics of mitochondria-targeting compounds and those of bola-amphiphiles. The anticancer effects of BPPB were assessed against HTLA-230 human stage-IV NB cells and their counterpart, which is resistant to etoposide (ETO), doxorubicin (DOX), and many other therapeutics (HTLA-ER). Very low IC

Indexed as

bola-amphiphileshigh-risk neuroblastoma (HR-NB)HTLA-230 NB and HTLA-ER cellsmitochondrial targetsnanosized vesiclestriphenyl phosphonium groups

Identifiers

PMID39330662
PMCPMC11434613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.